Alto Neuroscience, Inc. Securities Fraud Class Action Lawsuit Pending: Contact Levi & Korsinsky Before September 19, 2025 to Discuss Your Rights – ANRO

Core Viewpoint - A class action securities lawsuit has been filed against Alto Neuroscience, Inc. due to alleged securities fraud affecting investors who purchased shares during its initial public offering and subsequent period [1][2]. Group 1: Lawsuit Details - The lawsuit aims to recover losses for investors who acquired Alto common stock during its IPO on February 2, 2024, and those who purchased securities between February 2, 2024, and October 22, 2024 [2]. - The complaint alleges that the defendants made false statements regarding the effectiveness of the company's product pipeline, ALTO-100, in treating major depressive disorder, overstating its clinical, regulatory, and commercial prospects [3]. Group 2: Next Steps for Investors - Investors who suffered losses during the relevant timeframe have until September 19, 2025, to request appointment as lead plaintiff, although participation in any recovery does not require this [4]. - Class members may be entitled to compensation without any out-of-pocket costs or fees [4]. Group 3: Firm Background - Levi & Korsinsky, LLP has a strong track record in securities litigation, having secured hundreds of millions of dollars for shareholders over the past 20 years and consistently ranking among the top securities litigation firms in the United States [5].